Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 663-669, 2018.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-772383
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND@#Afatinib, a second-generation irreversible epidermal growth factor inhibitor receptor for the development of non-small cell lung cancer and secondary drug resistance, has low bioavailability and adverse reactions due to current oral administration. The aim of this study was to prepare a novel drug delivery system, afatinib liposome, and to establish a method for the determination of encapsulation efficiency.@*METHODS@#Four different preparation methods were used to prepare afatinib liposomes, and the optimal preparation process was determined by comparing the encapsulation efficiency and particle size.@*RESULTS@#It has been verified that sephadex microcolumn centrifugation can be used to purify afatinib liposomes, and UV spectrophotometry can be employed to determine the entrapment efficiency of liposomes. Among different preparation methods, the encapsulation efficiency of afatinib liposomes prepared by ammonium sulfate gradient method was 90.73% and the average particle size was 108.6 nm.@*CONCLUSIONS@#Ammonium sulfate gradient method can be successfully applied to prepare afatinib liposomes that performed higher encapsulation efficiency and smaller particle size. The UV spectrophotometry employed to determine the liposome encapsulation efficiency was easy operation and with high accuracy.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Quinazolinas
/
Cápsulas
/
Química
/
Carcinoma Pulmonar de Células não Pequenas
/
Usos Terapêuticos
/
Composição de Medicamentos
/
Tratamento Farmacológico
/
Afatinib
/
Lipossomos
/
Neoplasias Pulmonares
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2018
Tipo de documento:
Artigo